{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:54:11Z","timestamp":1790697251222,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"vor","delay-in-days":1035,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1038\/mtna.2014.57","type":"journal-article","created":{"date-parts":[[2014,10,28]],"date-time":"2014-10-28T12:20:03Z","timestamp":1414498803000},"page":"e206","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe Disease"],"prefix":"10.1016","volume":"3","author":[{"given":"Nicholas P","family":"Clayton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Weeden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J","family":"Moreland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald K","family":"Scheule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Leger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seng H","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M","family":"Wentworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mtna.2014.57_bib1","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1038\/mtna.2014.57_bib2","unstructured":"Myozyme Presecribing Infromation www.myozyme.com"},{"key":"10.1038\/mtna.2014.57_bib3","first-page":"132","article-title":"Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet Med"},{"key":"10.1038\/mtna.2014.57_bib4","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/mus.10381","article-title":"Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy","volume":"27","author":"Winkel","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1038\/mtna.2014.57_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1055\/s-2005-837543","article-title":"Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study","volume":"36","author":"Klinge","year":"2005","journal-title":"Neuropediatrics"},{"key":"10.1038\/mtna.2014.57_bib6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10545-007-0519-9","article-title":"Glycogen storage disease types I and II: treatment updates","volume":"30","author":"Koeberl","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/mtna.2014.57_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1038\/mtna.2014.57_bib8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet Med"},{"key":"10.1038\/mtna.2014.57_bib9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr Res."},{"key":"10.1038\/mtna.2014.57_bib10","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1038\/mtna.2014.57_bib11","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet Med"},{"key":"10.1038\/mtna.2014.57_bib12","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol Ther"},{"key":"10.1038\/mtna.2014.57_bib13","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1074\/jbc.M112.438663","article-title":"Glycosylation-independent lysosomal targeting of acid a-glucosidase enhances muscle glycogen clearance in pompe mice","volume":"288","author":"Maga","year":"2013","journal-title":"J Biol Chem."},{"key":"10.1038\/mtna.2014.57_bib14","doi-asserted-by":"crossref","first-page":"e40776","DOI":"10.1371\/journal.pone.0040776","article-title":"The pharmacological chaperone AT2220 increases recombinant human acid a-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease","volume":"7","author":"Khanna","year":"2012","journal-title":"PLoS ONE."},{"key":"10.1038\/mtna.2014.57_bib15","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1089\/hum.2008.010","article-title":"Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice","volume":"19","author":"Ziegler","year":"2008","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtna.2014.57_bib16","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/hum.2012.250","article-title":"Phase I\/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes","volume":"24","author":"Smith","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtna.2014.57_bib17","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","article-title":"The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement","volume":"26","author":"Cox","year":"2003","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/mtna.2014.57_bib18","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","article-title":"A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"key":"10.1038\/mtna.2014.57_bib19","doi-asserted-by":"crossref","first-page":"e15033","DOI":"10.1371\/journal.pone.0015033","article-title":"Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease","volume":"5","author":"Marshall","year":"2010","journal-title":"PLoS ONE."},{"key":"10.1038\/mtna.2014.57_bib20","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1042\/BJ20111416","article-title":"Glycogen and its metabolism: some new developments and old themes","volume":"441","author":"Roach","year":"2012","journal-title":"Biochem J"},{"key":"10.1038\/mtna.2014.57_bib21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ymgme.2010.05.001","article-title":"Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease","volume":"100","author":"Ashe","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mtna.2014.57_bib22","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2174\/156652312800840621","article-title":"Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges","volume":"12","author":"Arechavala-Gomeza","year":"2012","journal-title":"Curr Gene Ther"},{"key":"10.1038\/mtna.2014.57_bib23","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3390\/molecules14031304","article-title":"Gene knockdowns in adult animals: PPMOs and vivo-morpholinos","volume":"14","author":"Moulton","year":"2009","journal-title":"Molecules"},{"key":"10.1038\/mtna.2014.57_bib24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.bbrc.2007.04.172","article-title":"Achieving targeted and quantifiable alteration of mRNA splicing with Morpholino oligos","volume":"358","author":"Morcos","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1038\/mtna.2014.57_bib25","first-page":"3952","article-title":"Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy","volume":"117","author":"Wheeler","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1038\/mtna.2014.57_bib26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jchromb.2005.02.019","article-title":"A gel filtration assay to determine glycogen synthase activity","volume":"820","author":"Niederwanger","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1038\/mtna.2014.57_bib27","series-title":"Theory and Practice of Histological Techniques","first-page":"576","author":"Suvarna","year":"2013"},{"key":"10.1038\/mtna.2014.57_bib28","first-page":"Unit 26.8","article-title":"Using Morpholinos to control gene expression","author":"Moulton","year":"2008","journal-title":"Curr Protoc Mol Biol."},{"key":"10.1038\/mtna.2014.57_bib29","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/mt.2008.120","article-title":"Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice","volume":"16","author":"Jearawiriyapaisarn","year":"2008","journal-title":"Mol Ther"},{"key":"10.1038\/mtna.2014.57_bib30","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/hmg\/ddp535","article-title":"Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease","volume":"19","author":"Douillard-Guilloux","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1038\/mtna.2014.57_bib31","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1093\/hmg\/ddn290","article-title":"Modulation of glycogen synthesis by RNA interference: towards a new therapeutic approach for glycogenosis type II","volume":"17","author":"Douillard-Guilloux","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1038\/mtna.2014.57_bib32","doi-asserted-by":"crossref","first-page":"e56181","DOI":"10.1371\/journal.pone.0056181","article-title":"Dysregulation of multiple facets of glycogen metabolism in a murine model of Pompe disease","volume":"8","author":"Taylor","year":"2013","journal-title":"PLoS ONE."},{"key":"10.1038\/mtna.2014.57_bib33","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.bbamem.2010.02.012","article-title":"Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy","volume":"1798","author":"Moulton","year":"2010","journal-title":"Biochim Biophys Acta"}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253116303432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253116303432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T01:28:19Z","timestamp":1538098099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253116303432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":33,"alternative-id":["S2162253116303432"],"URL":"https:\/\/doi.org\/10.1038\/mtna.2014.57","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"article-number":"e206"}}